• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, July 10 The Hyderabad-based Dr Reddy’s Laboratories launched Glimy MP1 and Glimy MP2 for management of Type II diabetes.

Glimy MP, a triple drug combination (Glimepiride, Metformin and Pioglitazone) was an extension of the existing products of Dr Reddy’s, used in the management of Type 2 diabetes. It was a one step approach to intensive glycemic control, according to a release issued here.

The drug is available in dosages of 1mg (Glimy MP1) and 2mg (Glimy MP2), in sizes of 10 tabs /strip and 10 strips/pack.

The triple drug combination oral hypoglycemic agents market is about Rs 62 crore in size and has grown by 176 per cent in the last one year.

Diabetes is a metabolic disease with three anomalies i.e. reduced insulin secretion, decreased insulin sensitivity & increased hepatic glucose production.

Glimepiride would work by increasing the insulin secretion, Metformin acts by decreasing the hepatic glucose output while Pioglitazone would act by increasing the insulin sensitivity.

Thus, the triple combination would address all the three anomalies in diabetes, the release added.

More Stories on : Announcements | Pharmaceuticals | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Coal India move to fight corruption in procurement

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line